Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An announcement from Oxford BioDynamics ( (GB:OBD) ) is now available.
Oxford BioDynamics has announced that Georgetown University Medical Center will present clinical data on their EpiSwitch® CiRT test at the ASCO-GI Symposium. The CiRT test, which predicts the response to immune checkpoint inhibitors, has shown significant improvements in patient outcomes for liver and gastrointestinal cancers, indicating its potential as a vital tool for precision medicine and addressing unmet needs in cancer treatment.
More about Oxford BioDynamics
Oxford BioDynamics Plc is an international biotechnology company specializing in personalized healthcare through precision clinical diagnostic tests for life-changing diseases. Based in Oxford, UK, with operations in the US and Malaysia, the company offers the EpiSwitch® PSE and EpiSwitch® CiRT blood tests, which enhance the accuracy of prostate cancer screening and predict responses to immunotherapy, respectively. Their proprietary 3D genomic biomarker platform supports the development of new tests across various medical fields.
YTD Price Performance: -56.67%
Average Trading Volume: 3,343,828
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £2.08M
Learn more about OBD stock on TipRanks’ Stock Analysis page.
